Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease.

Authors

• Juhi Moon
• Robert H Hyland
• Fangqiu Zhang
• Diana M Brainard
• Sophie Lanzkron
• John G McHutchison
• Mark Sulkowski

Publication/Presentation Date

9-1-2017

Abstract

Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of fixed-dose combination ledipasvir and sofosbuvir for 12 weeks in this population.

Volume

65

Issue

5

First Page

864

Last Page

866

ISSN

1537-6591

Published In/Presented At

Moon, J., Hyland, R. H., Zhang, F., Brainard, D. M., Lanzkron, S., McHutchison, J. G., & Sulkowski, M. (2017). Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 65(5), 864–866. https://doi.org/10.1093/cid/cix441

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

28505305

Document Type

Article